文献速递浆细胞疾病

老年多发性骨髓瘤患者自报老年评估损害与治疗毒性相关

Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma.
PubMed 文献 · Blood Adv · 2026-01-01

该前瞻性研究纳入90例≥60岁开始新治疗的多发性骨髓瘤患者,基线及4个月完成电子综合老年评估和患者报告结局问卷。结果显示老年损害普遍,高龄、共病、功能受限和焦虑与高级别非血液学毒性显著相关;患者报告CTCAE毒性率高于医生报告,22%存在衰弱且与更差基线HRQOL和更多高级别非血液学毒性相关。

要点

  • 老年MM患者自报老年损害普遍,尤其身体功能域。
  • 高龄、共病、功能受限和焦虑与高级别非血液学毒性相关。
  • 患者报告CTCAE毒性率高于医生报告,需关注症状负担差异。

核心结论

  • 老年多发性骨髓瘤患者自报老年损害普遍,且与高级别非血液学毒性强烈相关。
  • 医生报告的CTCAE可能未完全反映患者症状负担。

研究设计与样本

  • 前瞻性研究,纳入90例≥60岁新诊断或复发难治多发性骨髓瘤开始新治疗的患者。
  • 基线及4个月完成电子综合老年评估和患者报告结局问卷,并推导累积缺陷衰弱指数。

主要发现

  • 高级别非血液学毒性与较高年龄、共病、患者报告功能受限和焦虑显著相关。
  • 患者报告CTCAE版本毒性率高于CTCAE,显示医生与患者报告毒性不一致。
  • 衰弱存在于22%患者,与更差基线HRQOL和增加的高级别非血液学毒性相关,但与治疗调整或医疗使用无关。
  • 平均CGA和HRQOL评分4个月内保持稳定,但个体轨迹各异。

临床怎么用

  • 对老年多发性骨髓瘤患者应进行综合老年评估,关注身体功能、共病和焦虑。
  • 临床应结合患者报告结局评估毒性,弥补医生报告CTCAE的不足。
  • 治疗期间需纵向评估老年状态,因个体轨迹存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frailty influences treatment outcomes in older patients with multiple myeloma (MM), yet existing frailty tools capture limited geriatric domains and are incompletely studied in the context of contemporary therapies. We prospectively evaluated patient-reported comprehensive geriatric assessment (CGA) domains and their associations with treatment toxicity and patient-reported outcomes (PRO) in older adults with MM. Patients aged ≥60 years with newly diagnosed or relapsed/refractory MM initiating a new therapy completed electronic CGA and PRO questionnaires at baseline and 4 months. Outcomes included clinician- and patient-reported treatment toxicity, treatment adaptations, health care use, and health-related quality of life (HRQOL). A cumulative deficit frailty index (FI) was derived from CGA and HRQOL domains. Among 90 patients (mean age, 72 years), geriatric impairments were common, particularly physical function domains. High-grade nonhematologic toxicities were significantly associated with older age, comorbidities, patient-reported functional limitations, and anxiety. Toxicity rates on the PRO version of the Common Terminology Criteria for Adverse Events (CTCAE) were higher than on CTCAE, highlighting a discordance between physician- and patient-reported treatment toxicity. Frailty was present in 22% and associated with worse baseline HRQOL and increased high-grade nonhematologic toxicity but not treatment adaptations or health care use. Average CGA and HRQOL scores remained stable over 4 months, although individual trajectories varied. Patient-reported geriatric impairments are prevalent in older adults with MM and strongly associated with nonhematologic toxicities even in the contemporary treatment era. Physician-reported CTCAE may not fully reflect patients' symptom burden. Heterogeneity in individual geriatric trajectories during treatment emphasize the need for longitudinal assessment. This study was registered at www.clinicaltrials.gov as NCT05918185.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abdallah N, Marar R, Yee C, et al. Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma. Blood Adv. 2026. PMID: 42508993. doi:10.1182/bloodadvances.2026020579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。